[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"corticobasal-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:corticobasal-syndrome":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,91,121,164,192,220,244],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100618613","digital-measurements-of-motor-and-voice-functions-in-ftd-100618613",false,"NCT07333898","Digital Measurements of Motor and Voice Functions in FTD","Inclusion Criteria:\n\n* Male and female participants aged 40 years or older with a clinical diagnosis of possible or probable FTLD syndrome phenotype.\n* Participants must be fluent in reading and speaking English and must be capable of providing informed consent based on the principal investigator's judgment.\n* Individuals eligible for inclusion must be able to comply with the protocol per the investigator's judgment and must have a caregiver or study partner who is willing and able to assist with all study-related procedures.\n\nExclusion Criteria:\n\n* Any neurological, medical, or psychiatric condition that would preclude or confound participation in study activities based on the investigator's judgment.\n* Individuals who have a history of frequent falls defined as more than 5 falls per month.","ALL","40 Years",{"count":18,"type":19},20,"ESTIMATED","OBSERVATIONAL","The primary objective of this clinical study is to provide the initial validation for monitoring biomarkers of symptoms and functioning for individuals with FTLD syndromes.\n\nResearchers at BioSensics and Johns Hopkins School of Medicine will use wearable sensors, computerized speech, psychomotor, and cognitive assessments to create outcome measures and digital biomarkers for FTLD syndromes. Researchers will deploy this digital health solution to monitor 20 patients with FTLD syndromes for 12 months with study visits every 3 months.",[23,24,25,26,27],"Frontotemporal Lobar Degeneration (FTLD)","Frontotemporal Dementia (FTD)","Corticobasal Syndrome","Corticobasal Syndrome(CBS)","Corticobasal Degeneration",[29,30,31],"digital health","wearable sensors","frontotemporal lobar degeneration","NOT_YET_RECRUITING","2026-04-23",{"date":35,"type":36},"2026-04-28","ACTUAL",{"date":38,"type":19},"2026-08-01",{"date":40,"type":19},"2028-12-31",{"name":42,"class":43},"BioSensics","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":15,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":54,"conditions":55,"keywords":73,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100565858","the-curepsp-genetics-program-100565858","NCT06647641","The CurePSP Genetics Program","Inclusion Criteria:\n\n1. Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions.\n2. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating\u002Freferring clinician.\n3. Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results.\n4. Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)\u002Fpower of attorney (POA), and have read, understood, and completed the informed consent form.\n5. Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).\n\nExclusion Criteria:\n\n1. Individuals who have received a blood transfusion within the past 3 months.\n2. Individuals who have active hematologic malignancies such as lymphoma or leukemia.\n3. Individuals who have had a bone marrow transplant within the past 5 years.\n4. Individuals under the age of 35 or age of majority in applicable states at the time of consenting.",true,"35 Years",{"count":53,"type":19},1000,"This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.\n\nUp to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.",[56,57,25,26,58,27,59,60,61,62,63,64,65,66,67,68,69,70,71,72],"PSP","PSP - Progressive Supranuclear Palsy","Corticobasal Degeneration Syndrome","Corticobasal Degeneration (CBD)","Corticobasal Syndrome (CBS)","MSA","MSA - Multiple System Atrophy","MSA-C","Multiple System Atrophy","Multiple System Atrophy (MSA) With Orthostatic Hypotension","Multiple System Atrophy - Cerebellar Subtype (MSA-C)","Multiple System Atrophy - Parkinsonian Subtype (MSA-P)","Multiple System Atrophy, Cerebellar Type","Multiple System Atrophy, Parkinsonian Type","Progressive Supranuclear Palsy","Progressive Supranuclear Palsy(PSP)","Progressive Supranuclear Palsy (PSP)",[74,70,64,75,76,56,61,77,78],"genetic study","Corticobasal","CurePSP","CBD","Genes","RECRUITING","2026-01-12",{"date":82,"type":36},"2026-01-14",{"date":84,"type":36},"2024-10-08",{"date":86,"type":19},"2030-12-31",{"name":88,"class":89},"Massachusetts General Hospital","OTHER",1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":15,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":90},"100489489","scrambler-therapy-for-corticobasal-syndrome-associated-pain-100489489","NCT05653778","Scrambler Therapy for Corticobasal Syndrome-Associated Pain","ST-CBS","Inclusion Criteria:\n\n* men and women, ≥50 years of age or older with CBS with an average daily pain rating of \\> 4 out of 10, using the following question from the Brief Pain Inventory: \"Please rate your pain by circling the one number that best describes your (abdominal) pain\u002Fdiscomfort on average over the past week. (Scale 0-10; 0= No pain, 10= Pain as bad as you can imagine)\n* English speakers or English proficiency\n* They must have a life expectancy \\> 90 days per their treating neurologist.\n* The patient must be able to understand the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form.\n\nExclusion Criteria:\n\n* Pregnant women, nursing women, women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device, surgical sterilization, subcutaneous implants, abstinence, etc.). Other exclusions include the following:\n* Use of an investigational agent for pain control concurrently or within the past 30 days,\n* History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation;\n* Patients with implantable drug delivery systems, e.g. Medtronic Synchromed, baclofen pumps.\n* Patients with heart stents or metal implants such as pacemakers, automatic defibrillators, cochlear implants, aneurysm clips, vena cava clips and skull plates. (Metal implants for orthopedic repair, e.g. pins, clips, plates, cages, joint replacements are allowed).\n* Medical exclusions include: patients with a history of myocardial infarction or ischemic heart disease within the past six months; patients with history of epilepsy, brain damage, or symptomatic brain metastases; skin conditions such as open sores that would prevent proper application of the electrodes; or other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study.","50 Years","89 Years",{"count":101,"type":19},25,"INTERVENTIONAL",[104],"NA","The goal of this pilot trial is to test whether scrambler therapy (ST) is an effective treatment for neuropathic pain in patients with corticobasal syndrome (CBS).\n\nThe main question it aims to answer is:\n\nWill ST reduce pain scores by at least 33% at one month in this pilot trial, justifying further multi-center trials?\n\nParticipants will:\n\n* be randomly assigned treatment from either transcutaneous electrical nerve stimulation (TENS) or ST for pain initially (eventually all patients will receive ST).\n* have superficial electrocardiogram (ECG) electrodes placed on the dermatomes involved with pain\n* obtain treatment lasting 30-40 minutes or until pain relief is obtained\n\nResearchers will compare patient's response to pain relief with TENS and ST to determine if ST is an effective treatment for central neuropathic pain.",[27,25,107],"Pain, Neuropathic",[27,109,110,111,112],"scrambler therapy","Corticobasal syndrome","neuropathic pain","neuropathy",{"date":114,"type":36},"2026-01-13",{"date":116,"type":36},"2024-04-05",{"date":118,"type":19},"2027-02",{"name":120,"class":89},"Johns Hopkins University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":15,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":132,"studyType":20,"phases":4,"briefSummary":133,"conditions":134,"keywords":143,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":163},"100556794","improving-prognostic-confidence-in-neurodegenerative-diseases-causing-dementia-using-peripheral-biomarkers-and-integrative-modeling-100556794","NCT06529744","Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling","CRND TorCA","Inclusion Criteria:\n\n* Possible or probable diagnosis of MCI or early dementia\n* Age 30-95\n* Study partner who has some weekly contact with patient. Some of the neuropsychological assessment require collateral from close contacts to assess cognition and functioning. Since neurodegenerative diseases can be associated with reduced cognition, including reduced awareness of one's own impairments, participants will be assessed for their capacity to consent at all study visits.\n* Must, in the opinion of the site investigator, be able to complete most study procedures.\n\nExclusion Criteria:\n\n* Participants who are not able to complete the majority of assessments in the opinion of the PI are excluded from the study. Exclusion criteria are evaluated at the site investigator's discretion; if the site investigator believes that the participant's symptoms are due to causes other than neurodegeneration, despite the presence of an exclusionary condition, the investigator may overrule the exclusion.","30 Years","95 Years",{"count":131,"type":19},500,"1 Year","To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease, including Alzheimer's Disease (AD), Lewy Body Disease (LBD), Vascular Disease (VaD) and Frontotemporal lobar degeneration (FTLD).",[135,136,137,138,139,140,25,70,141,142],"Dementia","Alzheimer Disease","Dementia With Lewy Bodies","Vascular Dementia","Frontotemporal Dementia","Mild Cognitive Impairment","Parkinson Disease","Primary Progressive Aphasia",[144,145,146,147,148,149,150,151,152,153],"alzheimer's disease","dementia","dementia with lewy bodies","vascular dementia","frontotemporal dementia","mild cognitive impairment","corticobasal syndrome","progressive supranuclear palsy","parkinson's disease","primary progressive aphasia","2025-11-17",{"date":156,"type":36},"2025-11-20",{"date":158,"type":36},"2023-11-11",{"date":160,"type":19},"2027-11",{"name":162,"class":89},"University Health Network, Toronto",4,{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":50,"sex":15,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":102,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":90},"100563210","stella-ftd-examination-of-a-behavior-change-intervention-for-ftd-family-care-partners-100563210","NCT06613204","STELLA-FTD: Examination of a Behavior Change Intervention for FTD Family Care Partners","STELLA-FTD","Inclusion Criteria: Family Care Partner\n\n* Adult caring for family member with FTD.\n* Provides 4 or more hours of care\u002Fweek. Does not have to reside with.\n* Identifies at least 2 moderately upsetting behaviors in the person with FTD.\n* Speaks and understands English to be able to participate in intervention.\n* Owns a telephone (smartphone, cell phone or landline).\n* Has email and mailing address to receive computer, study materials and surveys.\n* Provides informed consent to participate in the research.\n* Lives in the US\n\nInclusion Criteria: Person with FTD\n\n* Diagnosis of FTD\n* Family member of a Care Partner (this can be a relative, spouse, or close kin that is considered family).\n* Lives in US\n\nExclusion Criteria: Person with FTD\n\n* No Frontotemporal Degeneration diagnosis.\n* Unable to leave Care Partner during STELLA-FTD sessions.\n* Enrolled in hospice.\n\nExclusion Criteria: Family Care Partner\n\n* Unable to find activity for Care Recipient during STELLA-FTD sessions to allow Care Partner to work privately with Guide and other Care Partners.\n* Hearing and\u002For vision problems severe enough to prevent participation.\n* Refuses to be video-recorded during STELLA-FTD sessions.\n* Unwilling or unable to adequately follow study instructions and participate in study procedures.","18 Years","100 Years",{"count":174,"type":19},640,[104],"The purpose of this nationwide study is to test STELLA-FTD (Support via Telehealth: Living and Learning with Advancing Alzheimer's Disease)-FTD, an intervention to specifically address the needs of family Care Partners of persons with frontotemporal degeneration (FTD). STELLA-FTD is a multicomponent videoconference-based intervention designed to facilitate effective use of community and peer resources to foster effective management of behavioral and psychological symptoms of dementia. The study is recruiting families from across the United States.",[139,178,179,25],"Caregiver Burden","Primary Progressive Aphasia (PPA)",[181,182],"behavioral intervention","FTD","2025-10-23",{"date":185,"type":36},"2025-10-27",{"date":187,"type":36},"2025-06-23",{"date":189,"type":19},"2029-06",{"name":191,"class":89},"Oregon Health and Science University",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":50,"sex":15,"minAge":171,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":90},"100593008","imaging-studies-in-corticobasal-syndrome-100593008","NCT07000851","Imaging Studies in Corticobasal Syndrome","Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome","I-CAN","Inclusion Criteria:\n\n* Age 18 years or older\n* Meet possible or probable CBS criteria\n\nExclusion Criteria:\n\n* Subjects will be excluded if MRI is contraindicated (due to implanted device, severe claustrophobia, etc)\n* Subjects will be excluded if they have a concurrent illnesses or structural abnormality that could account for the CBS syndrome\n* Subjects will be excluded if they have a mutation in the progranulin gene\n* Subjects will excluded if they have received anti-Aβ therapy\n* Women who are pregnant will be excluded\n* Subjects will be excluded if they are actively taking daily anti-inflammatory medications (NSAIDs, corticosteriods, etc)\n* Subjects will be excluded if they have generalized inflammatory condition and treatment with immunosuppressive, corticoid\u002Fglucocorticoid, steroidal or non-steroidal anti-inflammatory medication within 2 weeks of scanning",{"count":201,"type":19},80,"The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.",[204,25,26,27,59,60],"Cortico Basal Degeneration",[206,207,208,209,150,210],"neurodegeneration","neurodegenerative disease","cbs","cbd","corticobasal degeneration","2025-07-03",{"date":213,"type":36},"2025-07-07",{"date":215,"type":36},"2025-06-25",{"date":217,"type":19},"2031-03-30",{"name":219,"class":89},"Jennifer Whitwell",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":50,"sex":15,"minAge":171,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":90},"100283059","diagnosing-frontotemporal-lobar-degeneration-100283059","NCT02964637","Diagnosing Frontotemporal Lobar Degeneration","Multimodal Assessment for Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration","Inclusion Criteria:\n\n* Participant must have a reliable study partner who can provide an independent evaluation of functioning.\n* Able to read, understand and speak English for neuropsychological testing.\n* All subjects must meet one of these diagnostic criteria (A) probable behavioral variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic variant PPA and \\[18F\\]T807 negative (D) probable CBS: using current criteria for CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy (NINDS-SPSP) (F) FTD-MND\n* Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and MMSE score equal to or greater than 28\n\nExclusion Criteria:\n\n* Patients with clinical, imaging or CSF A beta\u002F tau profile consistent with AD\n* History of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded.\n* Premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from PET study.\n* Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.","90 Years",{"count":229,"type":19},100,"To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes",[25,70,232,233,234,235],"Behavioral Variant Frontotemporal Dementia","Semantic Dementia","Progressive Nonfluent Aphasia","Amyotrophic Lateral Sclerosis And\u002For Frontotemporal Dementia","2025-03-25",{"date":238,"type":36},"2025-03-30",{"date":240,"type":4},"2015-08",{"date":242,"type":19},"2026-12",{"name":162,"class":89},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":15,"minAge":128,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":102,"phases":254,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100528533","phase-2-the-nadapt-study-a-randomized-double-blind-trial-of-nad-replenishment-therapy-for-atypical-parkinsonism-100528533","NCT06162013","The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism","NADAPT","Inclusion Criteria:\n\n1. Participant must understand the nature of the study and be able to provide written, informed consent.\n2. Male or female aged 30-85 years at baseline.\n3. 123I-Ioflupane dopamine transporter imaging (DaTSCAN) or FDOPA- PET has been performed. A negative DaTSCAN cannot be more than two years old at baseline.\n4. Meet the MDS criteria for possible or probable PSP; or\n5. Meet the MDS criteria for clinically possible or probable MSA; or\n6. Meet the consensus criteria for probable or possible CBS.\n7. A baseline PSPRS score of \\\u003C40 for PSP, or baseline UMSARS score \\\u003C 3 on items: 1, 2, 7-9.\n8. Score ≥ 20 on the Mini-Mental State Examination (MMSE) at screening.\n9. Able to ambulate independently or with assistance defined as the ability to take at least 5 steps with a walker (guarding is allowed provided there is no contact) or the ability to take at least 5 steps with the assistance of another person who can only have contact with one upper extremity.\n\nExclusion Criteria:\n\n1. Insufficient fluency in local language to complete neuropsychological and functional assessments.\n2. Evidence of differential diagnoses to PSP, MSA or CBS including: PD; dementia with Lewy bodies; Alzheimer's disease; motor neuron disease; history of repeated and\u002For major stroke; history of repeated and\u002For severe brain or spinal cord; history of neuroleptic use (except quetiapine) for prolonged period within the last 6 months; history of severe encephalitis; street drug-related parkinsonism; vascular parkinsonism; familial PSP, FTD, or known pathogenic MAPT mutation; prion disease; other neurological disease or MRI findings that could explain the PSP, MSA or CBS symptoms.\n3. Presence of other significant neurological or psychiatric disorders including (but not limited to) psychotic disorders; severe bipolar or unipolar depression; seizure disorder; tumor or other space-occupying lesion.\n4. Treatment with\u002Fuse of NR or any investigational drugs or device, within 90 days of screening.\n5. A history of alcohol or substance abuse within 1 year prior to baseline (Visit 1) and deemed to be clinically significant by the site investigator\n6. Any active neoplastic malignancy (other than non-metastatic dermatological conditions) within two years of the screening visit (Visit 0) or current clinically significant hematological, endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disease. Active neoplastic malignancy is defined as having a known malignant focus and\u002For receiving anti-cancer treatment. For the non-cancer conditions, if the condition has been stable for at least the one year before the screening visit (Visit 0) and\u002For is judged by the site investigator not to interfere with the subject's participation in the study, the subject may be included.\n7. Clinically significant laboratory abnormalities at screening that cannot be corrected to baseline and that is deemed incompatible with study participation by investigator.\n8. History of deep brain stimulator surgery other than sham surgery for deep brain stimulation (DBS) clinical trial.\n9. History of a clinically significant medical condition that would interfere with the subject's ability to comply with study instructions, would place the subject at increased risk, or might confound the interpretation of the study results.\n10. Severe dysphagia with inability to swallow study-drug safely at baseline.","85 Years",{"count":253,"type":19},330,[255],"PHASE2","Progressive supranuclear palsy (PSP), Multiple system atrophy (MSA) and corticobasal syndrome (CBS) are severe neurodegenerative diseases with rapid progression and no effective treatment. Patients quickly succumb to increasing motor and non-motor symptoms and survival ranges from \\~3 years to \\~10 years.\n\nAlthough PSP, MSA and CBS are rare diseases they constitute a major and mostly unaddressed challenge to health-care providers due to the severity of disease and lack of treatment.\n\nThe main hypothesis for the NADAPT trial is that oral administration of NR can boost cellular NAD levels in the central nervous system of patients with PSP, MSA and CBS, and rectify metabolism and inhibit neurodegeneration, resulting in delayed disease progression and amelioration of symptoms for these patients.\n\nTo test whether NR is a neuroprotective therapy for atypical parkinsonism, the investigators will perform the NADAPT clinical trial. The investigators will include 130 patients with Progressive supranuclear palsy (PSP), 165 patients with Multiple system atrophy (MSA) and an indeterminate number of patients with corticobasal syndrome (CBS). The participants will be stratified by disease into three cohorts and randomized to either 3000mg NR daily or placebo.\n\nThe trial will include patients from all of Norway. Patients will be followed for 78 weeks with both in-clinic visits and decentralized safety measurements and reporting of patient reported outcomes (PROMs). After completion of the 78 weeks follow-up, patients are offered to continue in an open-label NR-only extension study, this extension study will last until follow-up is completed for the last patients in NADAPT.",[70,64,25],"2025-01-09",{"date":260,"type":36},"2025-01-10",{"date":262,"type":36},"2024-03-05",{"date":264,"type":19},"2028-12",{"name":266,"class":89},"Haukeland University Hospital",3]